1. Home
  2. CSTL vs ANPA Comparison

CSTL vs ANPA Comparison

Compare CSTL & ANPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • ANPA
  • Stock Information
  • Founded
  • CSTL 2007
  • ANPA 2016
  • Country
  • CSTL United States
  • ANPA Hong Kong
  • Employees
  • CSTL N/A
  • ANPA N/A
  • Industry
  • CSTL Medical Specialities
  • ANPA
  • Sector
  • CSTL Health Care
  • ANPA
  • Exchange
  • CSTL Nasdaq
  • ANPA Nasdaq
  • Market Cap
  • CSTL 555.8M
  • ANPA 509.0M
  • IPO Year
  • CSTL 2019
  • ANPA 2025
  • Fundamental
  • Price
  • CSTL $24.21
  • ANPA $41.80
  • Analyst Decision
  • CSTL Strong Buy
  • ANPA
  • Analyst Count
  • CSTL 6
  • ANPA 0
  • Target Price
  • CSTL $37.67
  • ANPA N/A
  • AVG Volume (30 Days)
  • CSTL 712.7K
  • ANPA 42.6K
  • Earning Date
  • CSTL 08-04-2025
  • ANPA 01-01-0001
  • Dividend Yield
  • CSTL N/A
  • ANPA N/A
  • EPS Growth
  • CSTL N/A
  • ANPA 1.75
  • EPS
  • CSTL N/A
  • ANPA 0.07
  • Revenue
  • CSTL $346,269,000.00
  • ANPA $5,884,401.00
  • Revenue This Year
  • CSTL N/A
  • ANPA N/A
  • Revenue Next Year
  • CSTL N/A
  • ANPA N/A
  • P/E Ratio
  • CSTL N/A
  • ANPA $623.18
  • Revenue Growth
  • CSTL 20.40
  • ANPA N/A
  • 52 Week Low
  • CSTL $14.59
  • ANPA $2.80
  • 52 Week High
  • CSTL $35.84
  • ANPA $54.75
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 76.51
  • ANPA N/A
  • Support Level
  • CSTL $20.35
  • ANPA N/A
  • Resistance Level
  • CSTL $20.80
  • ANPA N/A
  • Average True Range (ATR)
  • CSTL 0.95
  • ANPA 0.00
  • MACD
  • CSTL 0.45
  • ANPA 0.00
  • Stochastic Oscillator
  • CSTL 96.67
  • ANPA 0.00

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.

Share on Social Networks: